论文部分内容阅读
目的探究CD56+表达对急性单核细胞白血病的临床效果。方法 32例急性单核细胞白血病(AML-M5)患者,随机分为CD56+组与CD56-组,各16例。对两组临床生物学特征、诱导缓解率、缓解时间及复发率进行对比观察。结果 CD56+组有7例高白细胞血症,CD56-组有3例高白细胞血症;CD56+组有13例髓外浸润,CD56-组有9例髓外浸润。CD56+组诱导缓解达CR约占56.25%,复发率68.75%,平均缓解时间为(4.2±2.1)个月,与CD56-组比较差异有统计学意义(P<0.05)。结论 CD56+急性单核细胞白血病患者非常容易患高白细胞血症与髓外浸润,且缓解率低,缓解期间短,复发率较高,预后差。
Objective To investigate the clinical effect of CD56 + expression on acute monocytic leukemia. Methods Thirty-two patients with acute monocytic leukemia (AML-M5) were randomly divided into CD56 + group and CD56- group, 16 cases in each group. The clinical biological characteristics, induction remission rate, remission time and recurrence rate were compared between the two groups. Results There were 7 cases of hyperlipidemia in CD56 + group, 3 cases of hyperlipidemia in CD56 - group, 13 cases of extramedullary infiltration in CD56 + group and 9 cases of extramedullary infiltration in CD56 - group. The CD56 + group induced a CR of about 56.25% and the recurrence rate was 68.75%. The mean remission time was (4.2 ± 2.1) months, which was significantly different from that of CD56- group (P <0.05). Conclusions Patients with CD56 + acute monocytic leukemia are highly susceptible to hypervolemic and extramedullary infiltration with a low response rate, short response time, and high recurrence rate with poor prognosis.